The state of Texas currently has 45 active clinical trials seeking participants for Depression research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/03/2025
Locations: Clinical Site, Austin, Texas +5 locations
Conditions: Bipolar Depression
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
Recruiting
The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression.
Gender:
ALL
Ages:
Between 25 years and 70 years
Trial Updated:
07/02/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Bipolar II Disorder, Depression, Bipolar, Suicidality
Tractography Guided Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression
Recruiting
Treatment resistant depression remains a major problem for individuals and society. Surgical procedures may provide relief for some of these patients. The most frequently considered surgical approach is deep brain stimulation (DBS) of a part of the brain called the subcallosal cingulate region. However, the effectiveness and safety is not well established. The investigators will use a novel approach using advanced imaging technique (magnetic resonance tractography) to evaluate the feasibility an... Read More
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
06/27/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Treatment Resistant Depression, Undergoing Deep Brain Stimulation (DBS) Surgery
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
Recruiting
This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major Depressive disorder (TRD) and will characterize the onset and durability of antidepressant effects of VLS-01-BU versus placebo.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/27/2025
Locations: Biobehavioral Research of Austin, Austin, Texas +1 locations
Conditions: Treatment Resistant Depression
Recovery Through Inspiration, Support, and Empowerment
Recruiting
The goal of this pilot study is to test the effectiveness of a novel intervention for young adults (ages 18-27) with mental health conditions who have been released from an acute care psychiatric facility. The intervention aims to reduce suicidality, depression, anxiety, re-hospitalization, and improve mental health recovery by using outpatient services. The current standard of care (SOC) for these patients at discharge includes a discharge plan with a list of their medications, anticipated out... Read More
Gender:
ALL
Ages:
Between 18 years and 27 years
Trial Updated:
06/26/2025
Locations: The University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Suicidal Ideation, Suicide Attempt, Anxiety, Depression Disorders
A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression
Recruiting
The purpose of this study is to o evaluate the antidepressant efficacy of the PEA in Bipolar Depression and the association between antidepressant response with endogenous cannabinoids and cytokine levels
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/25/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Bipolar Depression
A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD
Recruiting
The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD). The trial aims to determine: * If LPCN 1154A reduces depressive symptoms in subjects with severe PPD * How well LPCN 1154A is tolerated and what side effects it may cause * If LPCN 1154A reduces anxiety symptoms in subjects with severe PPD
Gender:
FEMALE
Ages:
Between 15 years and 45 years
Trial Updated:
06/18/2025
Locations: Maximos OB/GYN, League City, Texas
Conditions: Depression, Postpartum, Depression, Post-Partum, Postpartum Depression (PPD), Post-Natal Depression, Peripartum Depression, Postnatal Depression
Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression
Recruiting
We propose a clinical study of medial forebrain bundle DBS as a treatment in 20 patients with treatment refractory depression (TRD). Data from the University of Bonn indicates that surgical lesions of the medical forebrain bundle can produce therapeutic benefits in patients with depressive disorders, and suggest that DBS at the same site may also reduce symptomatology in these TRD patients (Schaepfer, 2013). Depression affects up to 10% of the US population and of those at least 10-15% do not be... Read More
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
06/17/2025
Locations: UT Center of Excellence on Mood Disorders, Houston, Texas
Conditions: Major Depressive Disorder, Treatment Resistant Depression
Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression
Recruiting
The overall objective of the investigators is to assess the therapeutic efficacy and tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow for treatment of treatment-resistant bipolar depression patient (TRBD).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Treatment-resistant Bipolar Depression
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
Recruiting
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. The treatment of the depressive episodes of bipolar disorder in the pediatric population has not been as widely studied as the treatment of depressive episodes in bipolar disorder in adults, therefore pharmacotherapeutic options are limited. Given the change in disease state and safety demonstrated in adults with depressive episodes associate... Read More
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
06/16/2025
Locations: BioBehavioral Research of Austin /ID# 227076, Austin, Texas +11 locations
Conditions: Depression, Bipolar I Disorder
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Recruiting
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: UT Health Austin, Mulva Clinic for the Neurosciences, Austin, Texas +7 locations
Conditions: Treatment Resistant Depression
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
Recruiting
Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: The University of Texas at Austin - Dell Medical School, Austin, Texas +6 locations
Conditions: Treatment Resistant Depression